Bone Marrow Macrophages Could Predict Resistance to Velcade, Study Suggests
The multiple myeloma therapy Velcade (bortezomib) can induce the formation of pro-inflammatory macrophages — a kind of white blood cell —…
News
Darzalex, Kyprolis, Dexamethasone Combo Extends Time to Disease Progression in Relapsed, Refractory Multiple Myeloma Patients, CANDOR Trial Results Show
A combination of Darzalex (daratumumab), Kyprolis (carfilzomib), and dexamethasone increases the time to disease progression or death in  multiple myeloma patients who…
FDA Approves Darzalex Combo for Newly Diagnosed Multiple Myeloma Patients Eligible for Transplant
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Velcade (bortezomib), thalidomide and dexamethasone…
CLR 131 Granted Orphan Drug Status in Europe for Myeloma Treatment
CLR 131, a a phospholipid drug conjugate (PDC) developed by Cellectar Biosciences, has been granted orphan drug status by the European Commission…
Carsgen’s CAR-T Cell Therapy Given Priority Designation in Europe for Multiple Myeloma
CT053, a novel cell-based therapy being developed by Carsgen Therapeutics, was given priority medicines (PRIME) status by the European Medicines Agency (EMA)…
Darzalex Combo Increases Response Rates in Newly Diagnosed Multiple Myeloma Patients, Trial Shows
Adding Darzalex (daratumumab) to a combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone — called the VRd combo — increases…
Investigational Antibody GBR 1342 Receives Orphan Drug Designation for Multiple Myeloma
GBR 1342, an investigational bispecific antibody developed by Glenmark Pharmaceuticals, was granted orphan drug designation by the U.S Food and Drug Administration (FDA) for…
Ygalo Continues to Show Promising Activity in Relapsed, Refractory Multiple Myeloma
Ygalo (melflufen) combination therapy continues to demonstrate promising results, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data…
Researchers Identify Promising Target for CAR T-cell Therapy in Myeloma
Designing CAR T-cells to specifically target GPRC5D — a protein appreciably present on the surface of myeloma cells — may be a safe and effective…
Cancer Patients Around the World to Receive Henry Schein ‘Comfort Kits’
Henry Schein, a foundation devoted to promoting dental and medical health, has produced more than 27,000 comfort kits for people fighting cancer in the U.S.
Recent Posts
- Germany clears pelareorep pancreatic cancer trial continuation
- FDA grants orphan drug status to novel brain cancer treatment
- Medicaid expansion can raise demand for gynecologic cancer care
- Under-the-skin Sarclisa found as effective as approved formulation
- FDA gives LYT-200 fast track status as potential AML treatment